Phase 2 N=11 Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Hyperphosphatemia · Kidney Disease
Primary: Serum Phosphorous Concentration — 2.0; 1.7 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Neuroendocrine Tumours
Primary: Disease Control Rate (DCR) Assessed Locally at Month 9 — 35.0; 45.2; 45.0 percentage of participants — p=0.2968
Phase 2 N=11 Pilot Study of Melatonin and Epilepsy
Epilepsy
Primary: Sleep Latency Wakefulness After Sleep Onset (WASO) — 42.3; 57.3 minutes/night
Phase 2 N=47 Assessing the Safety of Buprenorphine in People With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Subjects Who Require Hospitalization Within 72 Hours Post Conversion From Full Agonist Opioids to Buprenorphine-based Pain Treatment — 1 Participants
Phase 2 N=108 A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
Alzheimer Disease
Primary: Safety: Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 21; 10 Participants
Phase 2 N=4 Miltefosine to Treat Mucocutaneous Leishmaniasis
Mucosal Leishmaniasis · Cutaneous Leishmaniasis
Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants
Phase 2 N=36 Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance at Week 12 — 0.37; 0.00; 0.13 Wood Units (mmHg/L/min)
Phase 2 N=72 A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. — -13.19; -9.21; -9.2; -13.4 score on a…
Phase 2 N=117 FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Overall Survival (OS) — 5.4; 6.5 months — p=0.28
Phase 2 N=36 Losartan to Reverse Sickle Nephropathy
Nephropathy · Sickle Cell Anemia
Primary: Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline — 1; 7; 5 Participants
Phase 2 N=134 A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
Urticaria
Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57 — -19.16; -24.05; -11.25; -15.69 Score on a Scale — p=0.0559
Phase 2 N=144 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Soft Tissue Sarcoma · Bone Sarcoma
Primary: Objective Response Rate — 7; 2; 7 Participants
Phase 2 N=612 A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
HER2 Positive Breast Cancer
Primary: Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR) — 7.8; 5.6 months
Phase 2 N=182 A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 — -17.40; -5.85 score on a scale — p=<0.0001
Phase 2 N=30 Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Nonalcoholic Steatohepatitis
Primary: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) — 19.15; 1.25 milliseconds (ms) — p=0.1621